Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Antonis Kattamis, MD, Pranee Sutcharitchan, MD, Ali Taher, MDPhDFRCP, Maria Domenica Cappellini, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Vip Viprakasit, MD PhD

Blood (2017) 130 (Supplement 1): 4731.

https://doi.org/10.1182/blood.V130.Suppl_1.4731.4731

Published: 2017

Journal Articles

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Maria Domenica Cappellini, MD, Antonis Kattamis, MD, Vip Viprakasit, MD PhD, Pranee Sutcharitchan, MD, Dalia Mahmoud, Joseph Pariseau, PharmD, Abderrahmane Laadem, MD, Anzalee Khan, PhD, X. Henry Hu, MD PhD, Ali Taher, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 751.

https://doi.org/10.1182/blood.V130.Suppl_1.751.751

Published: 2017

Journal Articles

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

Ondrej Hrusak, MD PhD, Valerie De Haas, MD PhD, Ales Luks, Iveta Janotova, Ester Mejstrikova, MD PhD, Kirsten Bleckmann, MD, Anja Moricke, MD, Julie Irving, PhD, Benigna Konatkowska, Thomas B. Alexander, MD MPH, Hiroto Inaba, MD PhD, Kjeld Schmiegelow, MD DMSc, Simone Stokley, FRCPath,, Jorge Gabriel Rossi, PhD, Maria Sara Felice, MD PhD, Luciano Dalla-Pozza, MB BS FRACP, Jessa Morales, Michael Dworzak, MD, Barbara Buldini, MD, Giuseppe Basso, Myriam Campbell, Maria Elena Cabrera, Neda Marinov, Sarah Elitzur, MD, Shai Izraeli, MD, Drorit Luria, PhD, Tamar Feuerstein, PhD, Alexandra Kolenova, MD PhD, Peter Svec, Elena Kreminska, Karen R. Rabin, MD, Sophia Polychronopoulou, MD PhD, Elaine da Costa, Hanne Vibeke Marquart, MD PhD, Antonis Kattamis, MD, Richard Ratei, Dirk Reinhardt, MD PhD, Anthony V Moorman, PhD, Martin Schrappe, MD, Jan Stary, MD D.Sc.

Blood (2016) 128 (22): 584.

https://doi.org/10.1182/blood.V128.22.584.584

Published: 2016

Journal Articles

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2016) 128 (22): 1285.

https://doi.org/10.1182/blood.V128.22.1285.1285

Published: 2016

Journal Articles

The Changing Landscape of Treatment in Pediatric Aplastic Anemia; A Single Institution's Experience

Georgia Avgerinou, Katerina Katsibardi, Maria Filippidou, Natalia Tourkantoni, Eleni Atmatzidou, Kleoniki Roka, Nikoletta Selenti, Antonis Kattamis, MD

Blood (2016) 128 (22): 5082.

https://doi.org/10.1182/blood.V128.22.5082.5082

Published: 2016

Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Blood (2016) 128 (22): 850.

https://doi.org/10.1182/blood.V128.22.850.850

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

Occurrence of Neoplastic Diseases in a Large Cohort of Thalassemic Patients in Greece

Alexandra Kouraklis, MD, PhD, Antonia Chatziliami, MD, Antonis Kattamis, MD, PhD, Efthimia Vlachaki, MD, PhD, Evangelos Briasoulis, MD, PhD, Ioannis Lafiatis, MD, Polyxeni Lampropoulou, MD, Christina Fragodimitri, MD, Aggeliki Moira, MD, Argiris Symeonidis, MD, PhD

Blood (2012) 120 (21): 3264.

https://doi.org/10.1182/blood.V120.21.3264.3264

Published: 2012

Journal Articles

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

M Domenica Cappellini, MD, Amal El-Beshlawy, MD, John B Porter, MD, Antonis Kattamis, MD, PhD, Kerry Taylor, MD, Christian Rose, Vernon J Louw, MD, Ali El-Ali, MD, Nicolas Martin, MS, Norbert Gattermann, MD

Blood (2012) 120 (21): 5182.

https://doi.org/10.1182/blood.V120.21.5182.5182

Published: 2012

Journal Articles

Longitudinal Changes in Iron Overload Parameters and Iron Chelation Therapy in Young Patients with Thalassemia Major,

Antonis Kattamis, MD, Konstantinos Stokidis, MD, Polyxeni Delaporta, MD, Kyriakopoulou Dimitra, MD, Theoni Petropoulou, MD, Sorina Boiu, MD, Vassilis Ladis, MD

Blood (2011) 118 (21): 3202.

https://doi.org/10.1182/blood.V118.21.3202.3202

Published: 2011

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

Deferasirox Safety Profile in Patients with Transfusion-Dependent Anaemias:Results From the Interim Analysis of a Hellenic Study,

Vassilis Ladis, MD, Marouso Drossou, Dimitria Vini, Ersi Voskaridou, Miranda Athanasiou-Metaxa, Marina Oikonomou, Efthimia Vlachaki, Anna Tigka, Christos Tzavelas, Theodora Liakopoulou, Eleni Vrettou, Ioannis Adamopoulos, Antonis Kattamis, MD

Blood (2011) 118 (21): 3183.

https://doi.org/10.1182/blood.V118.21.3183.3183

Published: 2011

Journal Articles

No Mutations in the RPL11 Gene Detected in Greek Patients with Diamond Blackfan Anemia

Antonis Kattamis, MD, Polyxeni Delaporta, MD, Christalena Sofocleous, Maria Kalmanti, MD, PhD, Sophia Polychronopoulou, MD, Evagelia Lagona, MD, Marina Economou, MD, Lydia Kossiva, MD, Stavroula Kostaridou, MD

Blood (2011) 118 (21): 4856.

https://doi.org/10.1182/blood.V118.21.4856.4856

Published: 2011

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

NARROW

Physical Activities in Patients with β-Thalassemia As Measured By Fitbit in Association with Patient-Reported Outcomes

Quality of Life in Patients with β-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent

Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

The Changing Landscape of Treatment in Pediatric Aplastic Anemia; A Single Institution's Experience

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Occurrence of Neoplastic Diseases in a Large Cohort of Thalassemic Patients in Greece

Concomitant Medications and Gastrointestinal Events in Thalassemia and MDS Patients Receiving Deferasirox for Transfusional Iron Overload: Data From the EPIC Study

Longitudinal Changes in Iron Overload Parameters and Iron Chelation Therapy in Young Patients with Thalassemia Major,

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Deferasirox Safety Profile in Patients with Transfusion-Dependent Anaemias:Results From the Interim Analysis of a Hellenic Study,

No Mutations in the RPL11 Gene Detected in Greek Patients with Diamond Blackfan Anemia

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only